MilliporeSigma launched its BioContinuum Buffer Delivery Platform for next-generation bioprocessing, at INTERPHEX. The BioContinuum Buffer Delivery Platform is part of MilliporeSigma’s BioContinuum Platform for “contiGuous” bioprocessing.
 
The BioContinuum Buffer Delivery Platform is an integrated solution designed for more efficient buffer delivery and is tailored to provide the highest level of accuracy and precision in buffer preparation and management, according to the company. Its launch is timely, as industry adoption of liquid buffers is expected to expand from seven to 56%, according to MilliporeSigma’s internal market research.
 
MilliporeSigma obtained certain exclusive rights to sell the buffer dilution system developed by LEWA-Nikkiso America Inc. for customers involved in the development or production of diagnostics and biopharmaceuticals. This buffer dilution system offers the highest accuracy available for dilution of highly concentrated buffer. The BioContinuum Buffer Delivery Platform supplies process buffers with reduced resources and facility space, resulting in a more streamlined buffer suite and a more efficient manufacturing process. 
 
The configurable platform is comprised of four components: a selection of distinct buffer concentrates, delivered in Mobius Select single-use assemblies and an automated, precise buffer dilution system with tailored system services.
 
ContiGuous includes the orchestration and management of all the processing steps (materials, production, testing and analytics) with a streamlined and optimized approach. 

“MilliporeSigma’s vision goes beyond continuous manufacturing and will deliver contiGuous bioprocessing — a seamless confluence of digital and intensified bioprocessing building blocks,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “Our BioContinuum™ Buffer Delivery Platform is a perfect example of the high degree of connectivity that contiGuous biomanufacturing can achieve.”
 
MilliporeSigma also introduced Emprove Evolve, a new product line for regulatory support in risk assessment for critical raw materials, helping drug manufacturers meet developing regulatory requirements. The program contains a high level of product characterization and documentation, providing more control of the manufacturing process and allowing manufacturers to select the appropriate quality of raw materials for drug development.